All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit Know AML.
TRANSLATE
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Kura Oncology, Syndax, Abbvie, Thermo Fisher and Johnson & Johnson. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View AML content recommended for you
ASH 2022
23 Mar 2023
Revisit this:
🎥 #ASH22 | The AML Hub was pleased to speak to @alicemims_md, @OSUCCC_James. We asked, How can outcomes be improved in patients with molecularly-defined high-risk AML?
Find out more here 👉 https://t.co/ozxTbjbOYv.
#leusm #AMLsm
🎥 #ASH22 | The AML Hub was pleased to speak to @alicemims_md, @OSUCCC_James. We asked, How can outcomes be improved in patients with molecularly-defined high-risk AML?
Find out more here 👉 https://t.co/ozxTbjbOYv.
#leusm #AMLsm
17 Mar 2023
Revisit this:
🎥 #ASH22 | The AML Hub was pleased to speak to Courtney DiNardo, @MDAndersonNews. We asked, What do long-term data from the VIALE-A trial tell us about treatment with azacitidine + venetoclax?
Find out more here 👉 https://t.co/djeq64B5XO.
#amlsm #leusm
🎥 #ASH22 | The AML Hub was pleased to speak to Courtney DiNardo, @MDAndersonNews. We asked, What do long-term data from the VIALE-A trial tell us about treatment with azacitidine + venetoclax?
Find out more here 👉 https://t.co/djeq64B5XO.
#amlsm #leusm
11 Mar 2023
Revisit this:
🎥 #ASH22 | The AML Hub was pleased to speak to @DrAndyMatthews, @Penn. We asked, What do real-world data tell us about outcomes with venetoclax/HMA vs 7+3 chemotherapy?
Click here to hear what was said 👉 https://t.co/7eqK1t6GKA. #leusm #AMLsm
🎥 #ASH22 | The AML Hub was pleased to speak to @DrAndyMatthews, @Penn. We asked, What do real-world data tell us about outcomes with venetoclax/HMA vs 7+3 chemotherapy?
Click here to hear what was said 👉 https://t.co/7eqK1t6GKA. #leusm #AMLsm
7 Mar 2023
Does the presence of IDH mutation in patients with AML lead to higher rates of relapse after allo-HSCT? Are enasidenib and ivosidenib safe to use in these patients?
Read more in our latest article 👉 https://t.co/cewtrbqyUv. #ASH22 #leusm
Read more in our latest article 👉 https://t.co/cewtrbqyUv. #ASH22 #leusm
1 Mar 2023
Revisit this:
🎥 #ASH22 | The AML Hub was pleased to speak to @NicholasShortMD, University of Texas, Houston, US. We asked, How can serial MRD monitoring be utilized to improve relapse outcomes? Click here to see what was said 👇 https://t.co/UIyCmtOlHQ..
#amlsm
🎥 #ASH22 | The AML Hub was pleased to speak to @NicholasShortMD, University of Texas, Houston, US. We asked, How can serial MRD monitoring be utilized to improve relapse outcomes? Click here to see what was said 👇 https://t.co/UIyCmtOlHQ..
#amlsm
25 Feb 2023
Revisit this:
🎥 #ASH22 | The AML Hub was pleased to speak to @GhayasIssa, MD Anderson Cancer Centre, Houston, US. We asked, What do the data tell us about menin inhibition in relapsed/refractory AML? Click here to see what was said 👉 https://t.co/bqqQ8O75qi. #amlsm
🎥 #ASH22 | The AML Hub was pleased to speak to @GhayasIssa, MD Anderson Cancer Centre, Houston, US. We asked, What do the data tell us about menin inhibition in relapsed/refractory AML? Click here to see what was said 👉 https://t.co/bqqQ8O75qi. #amlsm
17 Feb 2023
Revisit this:
🎥 #ASH22 | During the 64th ASH Annual Meeting and Exposition, the AML Hub spoke with Ali Bazarbachi. We asked, Is NGS a useful clinical tool for the risk stratification of patients pre-transplant? Click here to see what they said: https://t.co/f5klwgRnXY #leusm
🎥 #ASH22 | During the 64th ASH Annual Meeting and Exposition, the AML Hub spoke with Ali Bazarbachi. We asked, Is NGS a useful clinical tool for the risk stratification of patients pre-transplant? Click here to see what they said: https://t.co/f5klwgRnXY #leusm
14 Feb 2023
What trials are currently investigating menin-KMT2A inhibition for the treatment of AML? Find out more about the novel therapies revumenib and ziftomenib, read our summary of the #ASH22 presentations by @GhayasIssa & Harry Erba 👉 https://t.co/wwCybuTAPR. #AMLsm #leusm #leukemia
31 Jan 2023
🎥 #ASH22 | The AML Hub was pleased to speak to @alicemims_md, @OSUCCC_James. We asked, How can outcomes be improved in patients with molecularly-defined high-risk AML?
Find out more here 👉 https://t.co/WsMxIE7luE.
#leusm #AMLsm
Find out more here 👉 https://t.co/WsMxIE7luE.
#leusm #AMLsm
27 Jan 2023
🎥 #ASH22 | The AML Hub was pleased to speak to Courtney DiNardo, @MDAndersonNews. We asked, What do long-term data from the VIALE-A trial tell us about treatment with azacitidine + venetoclax?
Find out more here 👉 https://t.co/ZQwngaFXs3.
#amlsm #leusm
Find out more here 👉 https://t.co/ZQwngaFXs3.
#amlsm #leusm
3 Jan 2023
🎥 #ASH22 | The AML Hub was pleased to speak to @DrAndyMatthews, @Penn. We asked, What do real-world data tell us about outcomes with venetoclax/HMA vs 7+3 chemotherapy? Click here to hear what was said https://t.co/SkxNREUYZN. #leusm #AMLsm
29 Dec 2022
Is olutasidenib a safe and effective treatment option for patients with IDH1-mutated R/R AML? Find out more from a phase II trial presented at #ASH22 👇 https://t.co/7M3EU85GUz.
#leusm #AMLsm
#leusm #AMLsm
27 Dec 2022
🎥 #ASH22 | The AML Hub was pleased to speak to @NicholasShortMD, University of Texas, Houston, US. We asked, How can serial MRD monitoring be utilized to improve relapse outcomes? Click here to see what was said 👇 https://t.co/x50HnW8v40.
#amlsm
#amlsm
23 Dec 2022
🎥 #ASH22 | The AML Hub was pleased to speak to @GhayasIssa, MD Anderson Cancer Centre, Houston, US. We asked, What do the data tell us about menin inhibition in relapsed/refractory AML? Click here to see what was said 👉 https://t.co/Q1wX2hai1y. #amlsm
19 Dec 2022
🎥 #ASH22 | During the 64th ASH Annual Meeting and Exposition, the AML Hub spoke with Ali Bazarbachi. We asked, Is NGS a useful clinical tool for the risk stratification of patients pre-transplant? Click here to see what they said: https://t.co/bcPFqENPFJ #leusm
14 Dec 2022
We hope you enjoyed following our live updates and congress coverage from #ASH22!
Keep an eye on our socials for post-congress key points and insights!
#hematology #medicalcongress #cancerresearch #cancerawareness #medicaleducation #leusm
Keep an eye on our socials for post-congress key points and insights!
#hematology #medicalcongress #cancerresearch #cancerawareness #medicaleducation #leusm
13 Dec 2022
RT @ALL_Hub_: CONGRESS | #ASH22
Drew Weissman, @WeissmanLab, discusses the development of RNA vaccinations for COVID-19 with the use of ant…
Drew Weissman, @WeissmanLab, discusses the development of RNA vaccinations for COVID-19 with the use of ant…
13 Dec 2022
RT @lymphomahub: CONGRESS |#ASH22
@bhwords of @GSTTnhs discusses the how COVID-19 has brought unforeseen challenges to the thrombosis comm…
@bhwords of @GSTTnhs discusses the how COVID-19 has brought unforeseen challenges to the thrombosis comm…
13 Dec 2022
CONGRESS | #ASH22
@profshanecrotty from @ljiresearch discusses SARS-CoV-2 and data gathered to access immunological memory post COVID-19 vaccinations with the involvement of long lasting germinal centres to priming immunizations.
@profshanecrotty from @ljiresearch discusses SARS-CoV-2 and data gathered to access immunological memory post COVID-19 vaccinations with the involvement of long lasting germinal centres to priming immunizations.
12 Dec 2022
Congress | #ASH22 @NicholasShortMD @MDAndersonNews discusses results from a phase I/II trial where the combination of azacitdine, venetoclax, and gilteritinib demonstrated efficacy in pts with mFLT3 AML. #leukemia #AMLsm
12 Dec 2022
Congress | #ASH22 @ColemanLindsley @DanaFarber gives a thought-provoking presentation on transplantation in pts with TP53-mutated MDS and AML. While outcomes are poor, allo-HSCT is associated with improved survival compared to not transplanting in pts with MDS. #leusm
12 Dec 2022
Congress | #ASH22 @charliecraddock Queen Elizabeth Hospital, Birmingham, delivers a fascinating talk on MRD in AML and how it can affect transplant decision-making. They highlight the impact of MRD positivity on conditioning regimens, stem cell source, and maintenance therapy.
12 Dec 2022
CONGRESS| #ASH22
Dr. Katherine Tarloc, of @seattlechildren discusses targeted therapies in pediatric #AML, using case-based scenarios, highlighting agents that are currently available and in clinical development for this patient subset.
#leusm #medicalcongress
Dr. Katherine Tarloc, of @seattlechildren discusses targeted therapies in pediatric #AML, using case-based scenarios, highlighting agents that are currently available and in clinical development for this patient subset.
#leusm #medicalcongress
12 Dec 2022
Congress | #ASH22 @jadothm @GSTTnhs @kingsmedicine discusses MRD in pts with mNPM1 AML receiving venetoclax-based therapies. An NPM1 copy number of <0.2 per 100 ABL, or a ≥3 log10 reduction diagnosis, in the BM within the first 6 months was associated with positive outcomes.
12 Dec 2022
Congress | #ASH22 @shengfcai @MSKCancerCenter shares updated results from the phase II/Ib Beat AML Master trial where enasidenib continued to be a safe, well-tolerated therapy in patients ≥60 years with ND mIDH2 AML alone and with the risk-adaption addition of venetoclax. #leusm
12 Dec 2022
CONGRESS | #ASH22
Amandeep Salhotra, @cityofhope, reports post-HSCT enasidenib maintenance to be well-tolerated in 15 patients with IDH2m AML, with anemia the most common AE. Outcomes were favorable; LFS was 100%, and cGvHD-free RFS almost 80%, at 12 and 24 months.
#leusm
Amandeep Salhotra, @cityofhope, reports post-HSCT enasidenib maintenance to be well-tolerated in 15 patients with IDH2m AML, with anemia the most common AE. Outcomes were favorable; LFS was 100%, and cGvHD-free RFS almost 80%, at 12 and 24 months.
#leusm
12 Dec 2022
CONGRESS | #ASH22
Olga Salamero @OlgaSalamero1, @vallhebron, reports the final data cut from the phase II ALICE trial. In 27 unfit patients with ND AML, the LSD1 inhibitor iadademstat + Aza gave ORR = 81% (CR/CRi = 52%), median DoR = 8.8 months. Median OS = 11.1 months.
#leusm
Olga Salamero @OlgaSalamero1, @vallhebron, reports the final data cut from the phase II ALICE trial. In 27 unfit patients with ND AML, the LSD1 inhibitor iadademstat + Aza gave ORR = 81% (CR/CRi = 52%), median DoR = 8.8 months. Median OS = 11.1 months.
#leusm
12 Dec 2022
Keep an eye on our Twitter page!
The @AML_Hub will be bringing you comprehensive updates as we continue our live coverage of #ASH22 Sessions covered today:
616, 723, 615, 732, Poster sessions, and education programs and sessions
#hematology #medicalcongress #cancerresearch
The @AML_Hub will be bringing you comprehensive updates as we continue our live coverage of #ASH22 Sessions covered today:
616, 723, 615, 732, Poster sessions, and education programs and sessions
#hematology #medicalcongress #cancerresearch
12 Dec 2022
CONGRESS | #ASH22
Jorge Cortes @GCC_Cortes adds that 34% patients who were platelet/RBC transfusion dependent at baseline achieved 56-day TI, across all response groups. 11% progressed to HSCT. #leusm
Jorge Cortes @GCC_Cortes adds that 34% patients who were platelet/RBC transfusion dependent at baseline achieved 56-day TI, across all response groups. 11% progressed to HSCT. #leusm
12 Dec 2022
CONGRESS | #ASH22
Jorge Cortes @GCC_Cortes, @GACancerCenter presents interim phase II data from Study 2102-HEM-101 of olutasidenib in R/R IDH1-mutated AML. CR/CRh rate = 35% (median duration 25.9 months) & ORR = 48% (n = 147). Median DOR = 11.7 months, OS = 11.6 months.
#leusm
Jorge Cortes @GCC_Cortes, @GACancerCenter presents interim phase II data from Study 2102-HEM-101 of olutasidenib in R/R IDH1-mutated AML. CR/CRh rate = 35% (median duration 25.9 months) & ORR = 48% (n = 147). Median DOR = 11.7 months, OS = 11.6 months.
#leusm
11 Dec 2022
Standing room only at the #ASH22 plenary session presenting the highest-caliber scientific abstracts at this years meeting. Johannes Schetelig @Medizin_TUD presents on the ASAP trial questioning the benefit of intensive remission induction chemo before allo-HCT in R/R #AML
11 Dec 2022
CONGRESS | #ASH22 Scott Solomon, @NorthsideHosp provides results from a phase II study indicating that autologous transplantation and post-transplant pembrolizumab is a safe and effective consolidation therapy for pts with non-favorable AML who are ineligible for allo-HSCT.#leusm
11 Dec 2022
CONGRESS | #ASH22 Christopher Eide, @OHSUKnight talks about the prospective profiling of venetoclax combinations, where they identified several combinations with activity that exceeds venetoclax + azacytidine in ex vivo assays. #AMLsm #leusm
11 Dec 2022
CONGRESS | #ASH22
Hartmut Döhner discussed relapse mechanisms in pts with mIDH1 newly-diangosed #AML receiving IVO + AZA. Clearance of mIDH1 and associated remission is seen with IVO + AZA treatment but other mutations can emerge to cause relapse.
#medicalcongress
Hartmut Döhner discussed relapse mechanisms in pts with mIDH1 newly-diangosed #AML receiving IVO + AZA. Clearance of mIDH1 and associated remission is seen with IVO + AZA treatment but other mutations can emerge to cause relapse.
#medicalcongress
11 Dec 2022
Keep an eye on our Twitter page!
The @AML_Hub will be covering the following session(s) today:
617, 731, Scientific and Education Program, and Plenary Scientific Session
Stay tuned for live updates, key insights, and interview coverage!
#ASH22 #hematology #medicalcongress
The @AML_Hub will be covering the following session(s) today:
617, 731, Scientific and Education Program, and Plenary Scientific Session
Stay tuned for live updates, key insights, and interview coverage!
#ASH22 #hematology #medicalcongress
10 Dec 2022
CONGRESS | #ASH22 @alipath @UWMedicine discusses the prevalence and prognostic significance of DNMT3A. mDNMT3A was found to be rare in younger pts. While pts with mDNMT3A/mNPM1 and mDNMT3A/mNPM1/mIDH had favorable outcomes, mDNMT3A/mIDH without mNPM1 conferred inferior OS. #leusm
10 Dec 2022
CONGRESS | #ASH22 @GhayasIssa @MDAndersonNews delivers an update on the phase I part of the AUGMENT-101 trial. Patients with R/R KMT2Ar or mNPM1 acute leukemia who received SNDX-5613 and proceeded to transplant experienced durable remissions. #AMLsm #leusm
10 Dec 2022
CONGRESS | #ASH22
@PratzKW shared long-term follow up data from the VIALE-A trial of venetoclax + azacitidine. Med follow up was 43.2 mo, med OS was 14.7 mo. Ven+aza provides long-term survival benefit with acceptable safety.
#leusm #medicalcongress
@PratzKW shared long-term follow up data from the VIALE-A trial of venetoclax + azacitidine. Med follow up was 43.2 mo, med OS was 14.7 mo. Ven+aza provides long-term survival benefit with acceptable safety.
#leusm #medicalcongress
10 Dec 2022
CONGRESS | #ASH22
Mina Abdelmalek @abdelmalek_mina describes CR/CRi rate = 82% for GO plus 7+3 vs 55% for 7+3. Post-CR/CRi relapse rate was 11% for GO plus 7+3 vs 44% for 7+3. #leusm
Mina Abdelmalek @abdelmalek_mina describes CR/CRi rate = 82% for GO plus 7+3 vs 55% for 7+3. Post-CR/CRi relapse rate was 11% for GO plus 7+3 vs 44% for 7+3. #leusm
10 Dec 2022
CONGRESS | #ASH22
Mina Abdelmalek @abdelmalek_mina of @UBuffalo presents data suggesting improved MRD negative CR and lower relapse rates in patients with intermediate-risk ND AML treated with gemtuzumab ozogamicin (GO) plus 7+3 (n = 33) induction vs 7+3 alone (n = 80). #leusm
Mina Abdelmalek @abdelmalek_mina of @UBuffalo presents data suggesting improved MRD negative CR and lower relapse rates in patients with intermediate-risk ND AML treated with gemtuzumab ozogamicin (GO) plus 7+3 (n = 33) induction vs 7+3 alone (n = 80). #leusm
10 Dec 2022
CONGRESS | #ASH22
Ghavas Issa @GhayasIssa shows, in 60 patients, ORR = 53%, CR/CRh = 30%, and MRD-negativity rate = 56% with revumenib. Median OS = 7.0 months, and median duration of CR/CRh = 9.1 months (n=18). #leusm
Ghavas Issa @GhayasIssa shows, in 60 patients, ORR = 53%, CR/CRh = 30%, and MRD-negativity rate = 56% with revumenib. Median OS = 7.0 months, and median duration of CR/CRh = 9.1 months (n=18). #leusm
10 Dec 2022
CONGRESS | #ASH22
Ghavas Issa @GhayasIssa of @MDAndersonNews presents data from AUGMENT-101 phase I trial of the menin-KMT2A interaction inhibitor revumenib (SNDX-5613) in R/R acute leukemia, including patients with KMT2Ar or NPM1 mutations.
#leusm
Ghavas Issa @GhayasIssa of @MDAndersonNews presents data from AUGMENT-101 phase I trial of the menin-KMT2A interaction inhibitor revumenib (SNDX-5613) in R/R acute leukemia, including patients with KMT2Ar or NPM1 mutations.
#leusm
10 Dec 2022
CONGRESS | #ASH22
Sameem Abedin @sameem_abedin, @MedicalCollege shows 53% 1 year OS and 32% at 2 years with salvage lintuzumab-Ac225 (actimab-A) plus CLAG-M in phase 1 trial in patients with R/R AML, with 64% progressing to allo-HSCT.
#leusm #medicalcongress
Sameem Abedin @sameem_abedin, @MedicalCollege shows 53% 1 year OS and 32% at 2 years with salvage lintuzumab-Ac225 (actimab-A) plus CLAG-M in phase 1 trial in patients with R/R AML, with 64% progressing to allo-HSCT.
#leusm #medicalcongress
10 Dec 2022
CONGRESS | #ASH22
Harry Erba showed that at 600mg ziftomenib, CR/CRh rate was 30% in patients with NPM1-mutations, and 5.6% in patients with KMT2A-rearrangments.
#leusm #medicalcongress
Harry Erba showed that at 600mg ziftomenib, CR/CRh rate was 30% in patients with NPM1-mutations, and 5.6% in patients with KMT2A-rearrangments.
#leusm #medicalcongress
10 Dec 2022
CONGRESS | #ASH22
Harry Erba @DukeCancer presents data from the KOMET-001 phase I/II trial showing the menin-KMT2A inhibitor ziftomenib (KO-539) has efficacy in R/R AML.
#leusm #medicalcongress
Harry Erba @DukeCancer presents data from the KOMET-001 phase I/II trial showing the menin-KMT2A inhibitor ziftomenib (KO-539) has efficacy in R/R AML.
#leusm #medicalcongress
6 Dec 2022
Get ready for #ASH22 with us!
The list of top abstracts selected by our steering committee for the 64th @ASH_hematology Annual Meeting and Exposition is now available on the @aml_hub!
📌Find out more: https://t.co/OFKs2gsSbW
#ASH2022 #leusm #medicaljournal #cancerresearch
The list of top abstracts selected by our steering committee for the 64th @ASH_hematology Annual Meeting and Exposition is now available on the @aml_hub!
📌Find out more: https://t.co/OFKs2gsSbW
#ASH2022 #leusm #medicaljournal #cancerresearch
1 Dec 2022
#ASH22 is almost upon us!
To help navigate the exciting sessions, check out our top abstract list on what’s hot in AML 👉 https://t.co/OFKs2gsSbW. #leusm
To help navigate the exciting sessions, check out our top abstract list on what’s hot in AML 👉 https://t.co/OFKs2gsSbW. #leusm
<span> </span>
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.
